Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND1 | P24385 | 9/20 | 0.56 |
| ▸ | CDK4 | P11802 | 6/20 | 0.56 |
| ▸ | CCND2 | P30279 | 1/20 | 0.56 |
| ▸ | CCND3 | P30281 | 1/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 10/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 9/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 8/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.46 |
| ▸ | CDK2 | P24941 | 7/20 | 0.46 |
| ▸ | CDK6 | Q00534 | 7/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.44 |
| ▸ | CDK9 | P50750 | 4/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11976959 | 0.95 | CCND1 (0.49) | CCND1CDK4CCND2CCND3MAPK8 | |
| SCHEMBL7712598 | 0.78 | AURKA (0.51) | CDK2 | |
| SCHEMBL4359995 | 0.72 | CCND1 (1.00) | CCND1CDK4CCND2CCND3MAPK8 | |
| SCHEMBL14327304 | 0.70 | CDK2 (0.46) | CCND1CDK4CCND2CCND3MAPK8 | |
| SCHEMBL24670367 | 0.69 | CCND1 (0.72) | CCND1CDK4CCND2CCND3MAPK8 | |
| SCHEMBL3304431 | 0.69 | CCND1 (0.72) | CCND1CDK4CCND2CCND3MAPK8 | |
| SCHEMBL7713198 | 0.69 | CDK4 (0.62) | CCND1CDK4CCND2CCND3CCNE1 | |
| SCHEMBL16802573 | 0.69 | MAPK8 (0.82) | CCND1CDK4CCND2CCND3MAPK8 | |
| SCHEMBL11976956 | 0.69 | JAK2 (0.57) | — | |
| SCHEMBL4200615 | 0.69 | CDK4 (0.49) | CCND1CDK4CCND2CCND3CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | PRKDC, TK2, PNKP | CCND1 615/4885CDK4 4/4885CCND2 629/4885 |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | PRKDC, TK2, PNKP | CCND1 615/4885CDK4 4/4885CCND2 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.